Trial reportDiabetes care2012
Analysis of glucose responses to automated insulin suspension with sensor-augmented pump therapy.
Trial report in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Fear of hypoglycemia in children with type 1 diabetes and their parents: Effect of pump therapy and continuous glucose monitoring with option of low glucose suspend in the CGM TIME trial.Pediatric diabetes · 2021Trial
- Trial
- Predictive Low-Glucose Insulin Suspension Reduces Duration of Nocturnal Hypoglycemia in Children Without Increasing Ketosis.Diabetes care · 2015Trial
- Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.The lancet. Diabetes & endocrinology · 2014Trial
- A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.Diabetes care · 2014Trial
- Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system.Diabetes care · 2014Trial
- Safety of nighttime 2-hour suspension of Basal insulin in pump-treated type 1 diabetes even in the absence of low glucose.Diabetes care · 2014Trial
- ASPIRE In-Home: rationale, design, and methods of a study to evaluate the safety and efficacy of automatic insulin suspension for nocturnal hypoglycemia.Journal of diabetes science and technology · 2013Trial
- Severe Hypoglycemia: Is It Still a Threat for Children and Adolescents With Type 1 Diabetes?Frontiers in endocrinology · 2020Review
- Combining continuous glucose monitoring and insulin pumps to automatically tune the basal insulin infusion in diabetes therapy: a review.Biomedical engineering online · 2019Review
- Design and Evaluation of a Robust PID Controller for a Fully Implantable Artificial Pancreas.Industrial & engineering chemistry research · 2015Article
- Current Trends in Continuous Glucose Monitoring.Journal of diabetes science and technology · 2014Review
- What Are the Next Steps in Continuous Glucose Monitoring?Journal of diabetes science and technology · 2014Review
- A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy.Diabetes, obesity & metabolism · 2013Review
- The artificial pancreas: is it important to understand how the β cell controls blood glucose?Journal of diabetes science and technology · 2013Review
- Article
- The role of continuous glucose monitoring in the care of children with type 1 diabetes.International journal of pediatric endocrinology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe advent of sensor-augmented pump therapy with a low-glucose suspend (LGS) function (Medtronic Paradigm Veo System), allowing insulin to be automatically suspended for up to 2 h when sensor glucose falls below a preset threshold, has the potential to reduce the duration of hypoglycemia. In this article, we analyzed blood glucose profiles following a full 2-h insulin suspension activated by the LGS function, as well as examined different patterns of use among patients. RESEARCH DESIGN AND
methodsData from a cohort of participants using the Veo System for up to 6 months were analyzed to determine the time and duration of insulin suspension activated by the LGS function. We further evaluated overnight suspend events with no patient response occurring prior to 3:00 a.m., which allowed us to determine the pattern of sensor glucose values with no patient intervention during and after the period of insulin suspension.
resultsThere were 3,128 LGS events during the 2,493 days evaluated. The median duration was 11.2 min, and 36% of events occurred overnight. There were 126 full 2-h suspend events that occurred overnight with no patient response, occurring before 3:00 a.m. For these events, the mean sensor glucose at the end of the 2-h suspend period was 99 ± 6 mg/dL ([means ± SE] 5.5 ± 0.3 mmol/L). The mean sensor glucose 2 h after insulin delivery resumed was 155 ± 10 mg/dL (8.6 ± 0.6 mmol/L). There were no episodes of severe hypoglycemia or diabetic ketoacidosis.
conclusionsAnalyses of sensor glucose patterns following insulin suspension activated by LGS suggest that this technology is safe and unlikely to be associated with adverse outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.